bioAffinity Technologies Inc Warrant 2022- on bioAffinity BIAFW 深 沪
已收盘 02-06 16:00:00 美东时间
0.31
0.000
0.00%
华盛通- 最 高0.32
- 今 开0.32
- 成交量 23股
- 最 低 0.32
- 昨 收 0.31
- 总市值 0
- 52周最高 0.8121
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.0525
- 委 比 33.33%
- 总股本 --
- 历史最高 4.50
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.0311
- 每 手 1
- 风险率 0.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioAffinity Technologies Gets Notification Of Allowance From United States Patent and Trademark Office For New Patent Covering AI-Built Algorithm, Flow Cytometry Platform To Detect Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially
2025-10-16 20:09
bioAffinity Technologies Reports Sales Of Its CyPath Lung Diagnostic Test For Lung Cancer Hit Record High In Q3 2025, Marking 95% Increase Over The Previous Quarter
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath® Lung diagnostic test for
2025-10-07 20:08
bioAffinity Technologies Prices $4.8M Public Offering Of ~1.92M Shares Of Common Stock Or Pre-Funded Warrants At A Price Of $2.50/Share
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a public offering of
2025-09-30 03:53
bioAffinity's CyPath Lung Diagnostic Detects Cancer In Challenging Case, Enabling Immediate Treatment Over Years Of Watchful Waiting
bioAffinity Technologies' noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatmentbioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a
2025-09-09 20:14
bioAffinity Technologies Announces $1.2M Capital Raise Through Private Placement Of 990 Series B Preferred Shares Convertible Into 4.3M Common Shares At $0.23/Share And 6.7M Warrants At $0.352/Share, Plus $253K Warrant Inducement For Immediate Exercise Of 1.1M Existing Warrants And Issuance Of 1.43M New Warrants
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into securities
2025-08-13 21:29
Bioaffinity Technologies Releases A New Case Study Of A Complex Clinical Case In Which Cypath Lung Identified Stage 1A Adenocarcinoma Lung Cancer In A Patient Whose Pet Imaging And Risk Model Probability Indicated A Low Risk Of Malignancy.
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company addressingthe need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex
2025-07-09 21:04
bioAffinity Technologies Announces It Has Been Awarded New U.S. Patent For Novel Broad Spectrum Cancer Therapeutics
Simultaneous siRNA Knockdown of Specific Cell Receptors Shown to Selectively Kill CancerCompany Research Targets Topical Application for Treatment of Skin CancersbioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), aSimultaneous siRNA Knockdown of Specific Cell Receptors Shown to Selectively Kill Cancer
2025-05-28 21:02
bioAffinity Technologies Names J. Michael Edwards As Chief Financial Officer
Edwards rejoins the Company after serving as interim CFObioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer,
2024-10-10 20:09
AMA Issues CPT Code for bioAffinity Technologies' CyPath Lung Test for Early-Stage Lung Cancer
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)))), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that the American Medical Association
2023-07-12 20:04
BioAffinity Technologies (NASDAQ:BIAFW) Shares Down 15.8%
bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) shares dropped 15.8%...
2023-02-02 16:32
